[go: up one dir, main page]

WO2008008348A3 - Procédé et compositions pour traiter un accident cérébro-vasculaire accompagné de fièvre - Google Patents

Procédé et compositions pour traiter un accident cérébro-vasculaire accompagné de fièvre Download PDF

Info

Publication number
WO2008008348A3
WO2008008348A3 PCT/US2007/015747 US2007015747W WO2008008348A3 WO 2008008348 A3 WO2008008348 A3 WO 2008008348A3 US 2007015747 W US2007015747 W US 2007015747W WO 2008008348 A3 WO2008008348 A3 WO 2008008348A3
Authority
WO
WIPO (PCT)
Prior art keywords
fever
compositions
treating stroke
stroke
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/015747
Other languages
English (en)
Other versions
WO2008008348A2 (fr
Inventor
Michael Tymianski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NoNO Inc
Arbor Vita Corp
Original Assignee
NoNO Inc
Arbor Vita Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PCT/US2007/015747 priority Critical patent/WO2008008348A2/fr
Priority to US12/307,581 priority patent/US8685925B2/en
Priority to EP07796769.3A priority patent/EP2043671B1/fr
Priority to ES07796769T priority patent/ES2804424T3/es
Priority to JP2009519493A priority patent/JP5746468B2/ja
Priority to CA2657665A priority patent/CA2657665C/fr
Application filed by NoNO Inc, Arbor Vita Corp filed Critical NoNO Inc
Priority to DK07796769.3T priority patent/DK2043671T3/da
Publication of WO2008008348A2 publication Critical patent/WO2008008348A2/fr
Publication of WO2008008348A3 publication Critical patent/WO2008008348A3/fr
Anticipated expiration legal-status Critical
Priority to US14/175,861 priority patent/US20140323406A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

L'invention concerne des procédés permettant de traiter un accident cérébro-vasculaire et les conditions apparentées exacerbées par la fièvre et/ou par une hyperglycémie en administrant des peptides ou des peptidomimétiques qui inhibent la liaison de NMDAR 2B à PSD-95 chez le patient.
PCT/US2007/015747 2006-07-11 2007-07-10 Procédé et compositions pour traiter un accident cérébro-vasculaire accompagné de fièvre Ceased WO2008008348A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US12/307,581 US8685925B2 (en) 2006-07-11 2007-07-10 Method and compositions for treating stroke with fever
EP07796769.3A EP2043671B1 (fr) 2006-07-11 2007-07-10 Peptide et composition de celui-ci pour son utilisation dans le traitement d'un accident cérébro-vasculaire accompagné de fièvre
ES07796769T ES2804424T3 (es) 2006-07-11 2007-07-10 Péptido y composición del mismo para usar en el tratamiento del accidente cerebrovascular con fiebre
JP2009519493A JP5746468B2 (ja) 2006-07-11 2007-07-10 発熱を伴う脳卒中を処置する方法および組成物
CA2657665A CA2657665C (fr) 2006-07-11 2007-07-10 Procede et compositions pour traiter un accident cerebro-vasculaire accompagne de fievre
PCT/US2007/015747 WO2008008348A2 (fr) 2006-07-11 2007-07-10 Procédé et compositions pour traiter un accident cérébro-vasculaire accompagné de fièvre
DK07796769.3T DK2043671T3 (da) 2006-07-11 2007-07-10 Peptid og sammensætning deraf til anvendelse ved behandling af slagtilfælde med feber
US14/175,861 US20140323406A1 (en) 2006-07-11 2014-02-07 Method and compositions for treating stroke with fever

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83018906P 2006-07-11 2006-07-11
US60/830,189 2006-07-11
US83357206P 2006-07-26 2006-07-26
US60/833,572 2006-07-26
PCT/US2007/015747 WO2008008348A2 (fr) 2006-07-11 2007-07-10 Procédé et compositions pour traiter un accident cérébro-vasculaire accompagné de fièvre

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/307,581 A-371-Of-International US8685925B2 (en) 2006-07-11 2007-07-10 Method and compositions for treating stroke with fever
US14/175,861 Continuation US20140323406A1 (en) 2006-07-11 2014-02-07 Method and compositions for treating stroke with fever

Publications (2)

Publication Number Publication Date
WO2008008348A2 WO2008008348A2 (fr) 2008-01-17
WO2008008348A3 true WO2008008348A3 (fr) 2008-06-12

Family

ID=38923841

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/015747 Ceased WO2008008348A2 (fr) 2006-07-11 2007-07-10 Procédé et compositions pour traiter un accident cérébro-vasculaire accompagné de fièvre

Country Status (7)

Country Link
US (2) US8685925B2 (fr)
EP (1) EP2043671B1 (fr)
JP (2) JP5746468B2 (fr)
CA (1) CA2657665C (fr)
DK (1) DK2043671T3 (fr)
ES (1) ES2804424T3 (fr)
WO (1) WO2008008348A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
US8933013B2 (en) * 2007-12-05 2015-01-13 Nono Inc. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
DK2320927T3 (en) 2008-07-09 2015-09-14 Univ Copenhagen Modified peptides as potent inhibitors of the PSD-95 / NMDA receptor interaction
WO2010144721A2 (fr) 2009-06-10 2010-12-16 Arbor Vita Corporation Systèmes modèles et régimes de traitement pour un traitement de maladies neurologiques
US9139615B2 (en) 2011-05-13 2015-09-22 University Of Copenhagen High-affinity, dimeric inhibitors of PSD-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain
SG194717A1 (en) * 2011-05-13 2013-12-30 Koebenhavns Uni University Of Copenhagen High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants againstischemic brain damage and for treatment of pain
HRP20220519T1 (hr) * 2011-06-24 2022-05-27 Nono Inc. Kombinacijska terapija ishemije
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
US9680916B2 (en) 2013-08-01 2017-06-13 Flowtraq, Inc. Methods and systems for distribution and retrieval of network traffic records
EP3371212B1 (fr) 2015-11-06 2023-10-11 The Board of Trustees of the University of Illinois Peptides et procédé de traitement de l'arrêt cardiaque
JP7002788B2 (ja) * 2017-07-05 2022-03-03 拜西欧斯（北京）生物技術有限公司 ポリペプチドの薬学的に許容される塩およびその使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059597A1 (en) * 1999-06-02 2005-03-17 Michael Tymianski Method of reducing injury to mammalian cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991005058A1 (fr) 1989-10-05 1991-04-18 Glenn Kawasaki Synthese et isolation sans cellule de nouveaux genes et de nouveaux polypeptides
US5747334A (en) 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
WO2004045535A2 (fr) * 2002-11-14 2004-06-03 Arbor Vita Corporation Interactions moleculaires dans des neurones
CA2551190A1 (fr) 2003-12-23 2005-07-07 Nono Inc. Polypeptides pour la modulation de la liaison des proteines du canal de recepteur de potentiel transitoire et proteines associees au recepteur de potentiel transitoire
EP1884521A1 (fr) 2006-07-31 2008-02-06 Xigen S.A. Peptide de fusion pour inhiber l'interaction du récepteur neuronal NMDA (NMDAR) avec les protéines interagissant avec le récepteur NMDA
EP2120987B1 (fr) * 2007-03-02 2014-01-15 NoNO Inc. Traitement des incidents cérébrovasculaires et d'autres maladies sans inhibition des canaux calcium de type n
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059597A1 (en) * 1999-06-02 2005-03-17 Michael Tymianski Method of reducing injury to mammalian cells

Also Published As

Publication number Publication date
US20120208764A1 (en) 2012-08-16
EP2043671A2 (fr) 2009-04-08
CA2657665A1 (fr) 2008-01-17
US20140323406A1 (en) 2014-10-30
JP2009544585A (ja) 2009-12-17
JP2013151495A (ja) 2013-08-08
WO2008008348A2 (fr) 2008-01-17
JP5746468B2 (ja) 2015-07-08
DK2043671T3 (da) 2020-06-15
EP2043671A4 (fr) 2010-09-15
CA2657665C (fr) 2015-06-02
ES2804424T3 (es) 2021-02-08
US8685925B2 (en) 2014-04-01
JP6088272B2 (ja) 2017-03-01
EP2043671B1 (fr) 2020-05-20

Similar Documents

Publication Publication Date Title
WO2008008348A3 (fr) Procédé et compositions pour traiter un accident cérébro-vasculaire accompagné de fièvre
MY146969A (en) Dpp iv inhibitor formulations
WO2008097835A3 (fr) Compositions et procédés de traitement de troubles métaboliques
ZA200708361B (en) Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition
MY150602A (en) Subtituted-quinoxaline-type piperidine compounds and the uses thereof
MX2010006823A (es) Metodos para el tratamiento de la gota.
WO2009129246A3 (fr) Compositions et leurs procédés de préparation et d'utilisation
WO2009118662A3 (fr) Compositions et méthodes de traitement de la perte osseuse
WO2008060374A3 (fr) Procédés et compositions utiles pour une cicatrisation de plaie chez les diabétiques
HN2008001720A (es) Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina
WO2008064242A3 (fr) Systèmes de chromatographie comprenant des composants à usage unique
EP2039705A4 (fr) Caoutchouc diénique modifié et composition de caoutchouc le contenant
WO2008025020A3 (fr) agents de liaison de CD30 et leurs usages
WO2008133722A3 (fr) Anticorps et diagnostics
EP1986702A4 (fr) Procédés, systèmes et compositions d'hyperporalisation
UA99540C2 (ru) Замещенные мостиковым хиноксалином пиперидиновые соединения и их применение
WO2010072787A3 (fr) Composition et méthode de traitement d'états pathologiques cutanés
WO2007084857A3 (fr) Procédés et compositions de traitement de troubles prolifératifs cellulaires
CL2008000303A1 (es) Compuestos derivados de 1-oxa-3-azaespiro[4.5]decan-2-ona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un trastorno de la alimentacion, obesidad, depresion.
WO2007075439A3 (fr) Compositions et methodes pour traiter l'obesite et des troubles metaboliques associes
WO2008079270A3 (fr) Coadministration d'alpha-foetoprotéine et d'un agent immunomodulateur pour traiter la sclérose en plaques
WO2007144057A3 (fr) Carbone antimicrobien
WO2008033333A3 (fr) Variants de la famille il-1
IL196561A0 (en) Compositions and methods for treating diabetes and neuropsychological dysfunction
WO2008100629A3 (fr) Mimétiques de la glutathione peroxydase pour le traitement de dermatoses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07796769

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2657665

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009519493

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007796769

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 12307581

Country of ref document: US